Key Points
Roth Capital maintained Buy rating on RSSS while cutting price target to $3.50 from $5.00.
Stock trades at $2.39, down 11.8% today with market cap of $78.6 million.
Meyka AI grades RSSS as B+ with two Buy ratings and no Sell recommendations.
Company shows 9.9% revenue growth but faces margin pressure with 7.9% net profit margin.
Roth Capital maintained its Buy rating on Research Solutions, Inc. (RSSS) on May 15, 2026, though the analyst firm significantly reduced its price target. The new target of $3.50 represents a substantial cut from the previous $5.00 level, signaling caution about near-term momentum. Despite the downward revision, the analyst rating remained unchanged, suggesting confidence in the company’s long-term direction. RSSS trades at $2.39, down 11.8% on the day as the market digests the revised outlook.
Roth Capital Maintains Buy Despite Price Target Cut
Roth Capital’s decision to maintain its Buy rating while cutting the price target reflects a nuanced view of Research Solutions. The analyst firm reduced its 12-month price target to $3.50 from $5.00, a 30% reduction that signals concerns about valuation and near-term catalysts.
The maintained rating suggests the analyst still believes in the company’s fundamental business model. Research Solutions provides cloud-based software and scientific content access to life science organizations. The company operates in the competitive Software-Application sector, where growth and profitability matter significantly. Roth Capital’s price target revision reflects market realities rather than operational deterioration.
Stock Performance and Technical Metrics
RSSS has faced significant headwinds recently, with the stock down 11.8% today and 18.7% year-to-date. The stock trades above its 50-day average of $2.43 and 200-day average of $2.86, though well below its 52-week high of $4.12. The company has a market cap of $78.6 million with 32.9 million shares outstanding.
Key financial metrics show mixed signals. The stock trades at a P/E ratio of 21.5, elevated for a small-cap software company. Revenue per share stands at $1.57, while earnings per share reached $0.12. Free cash flow per share of $0.24 demonstrates the company generates cash, though profitability remains modest at a 7.9% net margin.
Meyka AI Stock Grade and Analyst Consensus
Meyka AI rates RSSS with a grade of B+, reflecting solid fundamentals despite recent weakness. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests the stock has merit for patient investors, though near-term volatility remains likely.
Analyst consensus shows two Buy ratings with no Hold or Sell recommendations, indicating broad optimism among coverage firms. The company’s ROE of 26.7% and ROA of 8.8% demonstrate efficient capital deployment. However, the current ratio of 0.79 raises liquidity concerns, suggesting the company operates with tight working capital management.
Growth Trajectory and Forward Outlook
Research Solutions posted 9.9% revenue growth in its latest fiscal year, with gross profit expanding 23.2%. Operating income surged 4.3%, though net income grew only 1.3%, indicating margin pressure. The company’s three-year revenue growth per share reached 28.3%, showing consistent expansion in its core markets.
Meyka’s AI price forecast projects RSSS at $2.70 annually, suggesting limited upside from current levels. The five-year forecast declines to $1.38, reflecting analyst concerns about long-term competitive positioning. Earnings are scheduled for September 17, 2026, which could provide clarity on management’s strategy and market conditions.
Final Thoughts
Roth Capital’s maintained Buy rating on Research Solutions reflects confidence in the company’s business model despite cutting its price target by 30%. The analyst rating maintained status indicates the firm sees value at lower prices, though near-term headwinds persist. With RSSS trading at $2.39 and a market cap of $78.6 million, the stock remains a small-cap play requiring careful monitoring. Investors should await September earnings to assess whether management can reignite growth momentum and justify the analyst’s constructive stance.
FAQs
Roth Capital reduced its price target from $5.00 to $3.50, reflecting valuation concerns and limited near-term catalysts. The 30% cut signals caution while maintaining a Buy rating, suggesting value at lower prices.
Two analysts rate RSSS as Buy with no Hold or Sell recommendations. Roth Capital maintained its Buy rating on May 15, 2026, indicating broad optimism despite recent stock weakness.
Meyka AI assigns RSSS a B+ grade based on S&P 500 comparison, sector performance, financial growth, and analyst consensus. This suggests solid fundamentals, though near-term volatility remains likely.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)